A Comparative Study Between Palonosetron and Granisetron to Prevent Post Operative Nausea and Vomiting after Gynaecological Surgery

Rekha Solanki, Nita Dhiru Gosai, Raushan Kumar Jha, Cherian Roy, Vibhuti Chaudhari, Bipin Patel


Aim: Our aim of this randomized & prospective clinical study was to investigate and compare the efficacy of palonosetron HCl and granisetron HCl to prevent postoperative nausea and vomiting after gynaecological surgery.

Method: Fifty female patients of ASA grade I and II in between 18-60 years of age posted for elective gynaecological surgery were randomly divided into two groups containing 25 patients each.

Before induction of anaesthesia group P received bolus dose of palonosetron 75 mcg and group G received bolus dose of granisetron 2.5 mg intravenously   slowly over a period of 30 seconds.

Result: In the postoperative period (0-3 hrs), the incidence of complete response (no postoperative nausea & vomiting, no rescue medication) was 88% with palonosetron and 76% with granisetron (p value-0.46). During 3-24 hrs postoperatively the incidence was 92% with palonosetron and 80% with granisetron (p value-0.417).  During 24-48 hrs postoperatively the incidence was 92 % with palonosetron and 60 % with granisetron (p value-0.018). During 48-72 hrs incidence was statistically insignificant (p value-0.1284). Insignificant incidence of side effects between the groups was found.

Conclusion: Palonosetron is more potent and long acting than granisetron for the prevention of post operative nausea & vomiting after gynaecological surgery.


Gynaecological Surgery, Palonosetron, Granisetron,Post operative nausea and vomiting.

Full Text:



Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. 1992; 77:162-84.

Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk scores for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999; 91:693-700.

Kim SI, Kim SC, Baek YH, Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery. Br J Anaesth. 2009; 103:549-53.

Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol. 2006; 19:606-11.

Newberry NR, Watkins CJ, Sprosen TS, Blackburn TP, Grahame-Smith DG, Leslie RA. BRL 46470 potently antagonizes neural responses activated by 5-HT 3 receptors. Neuropharmacology. 1993; 32:729–35.

Elliott P, Seemungal BM, Wallis DI. Antagonism of the effects of 5-hydroxytryptamine on the rabbit isolated vagus nerve by BRL 43694 and metoclopramide. Naunyn-Schmiedebergs Archives of Pharmacology. 1990; 341:503–9.

Rojas C, Stathis M, Thomas A, Massuda E, Alt J, Zhang J, Rubenstein E, Sebastianis S, Canloreggi S, Snyder SH, Slusher B. Palonosetron exhibits unique molecular interactions with the 5-HT 3 receptor. Anesth Analg. 2008; 107:469–78.

Gralla R, Lichinitser M, Vander Vegt S, Palonosetron improves prevention of chemotherapy induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2003; 14:1570- 7.

Dtsch Arztebl. Nausea and Vomiting After Surgery under General Anesthesia. Int. 2010; 107: 733–41.

Bermudez J, Boyle EA, Minter WD, Sanger GJ. The antiemetic potential of the 5-hydroxytryptamine 3 receptor antagonist BR 43694. Br J Cancer. 1988; 58:644–50.

Carmichel J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRI 43694A), a selective 5-HT 3 receptor antagonist: correlation of antiemetic response. Cancer Chemother Pharmacol. 1989; 24:45–9.

Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs: optimal dose finding study. J Clin Ther Med. 1990; 6:49–61.

Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C. A randomized double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting over a 72 hour period. Anesth Analg. 2008; 107:445–51.

Chun H. R., Jeon I. S., Park S. Y., Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial BJA. 2015; 1:115.

Aapro MS, Macciocchi A, Gridelli C. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol 2005; 3:369-74.

Aapro MS, Grunberg SM, Manikhas GM, Olivares G et al. A phase 3, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17:1441-9.

Bhattacharjee Dhurjoti Prosad, Dawn Satrajit. A Comparative Study between Palonosetron and Granisetron to prevent Postoperative Nausea and Vomiting after Laparoscopic Cholecystectomy. J Anaesthesiol Clin Pharmacol. 2010; 26: 480–3.

DOI: http://dx.doi.org/10.7439/ijbar.v6i9.2523

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


  • There are currently no refbacks.

Copyright (c) 2015 International Journal of Biomedical and Advance Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.